drugset / Trial / NCT00472836

Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

NCT00472836

Phase 1 Completed 17 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism. This study will therefore compare the pharmacokinetics (time course of drug concentrations in the body), safety and tolerability of CP-945,598 in patients with severe renal impairment and healthy control subjects.

Timeline

Start
2007-06
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject OTENABANT Small molecule

Indications